# Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

Source: https://onco.cc/trials/nct05268692/  
OnCo record `nct05268692` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Kochi University, now recruiting.

## Summary

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP is a phase 2/3, randomised interventional study registered as NCT05268692 by Kochi University, with a registry enrolment figure of 500 participants, started 2019-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: GS; GnP. Conditions listed: Pancreatic Adenocarcinoma. Primary outcome: overall survival. Pancreatic eligibility wording from the registry: "elective pancreatectomy for pancreatic cancer". Sites: Japan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05268692
- Phase: 2/3
- Setting: Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP
- Sponsor: Kochi University
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT05268692: https://clinicaltrials.gov/study/NCT05268692

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05268692.json